Early recognition is critical to improving outcomes in adult HLH. This episode explores the clinical features, common triggers, and laboratory abnormalities that should raise suspicion for HLH, while reviewing the strengths and limitations of current diagnostic tools, including the HLH-2004 criteria, HScore, and emerging biomarker strategies. Faculty also discuss how trends in ferritin and immune biomarkers can support earlier diagnosis and more informed risk stratification.

Launch/Release Date: July 23, 2026

Activity Expiration Date: June 30, 2027

Faculty

Sarah Nikiforow, MD, PhD

Assistant Professor, Stem Cell Transplantation

Medical Director, DFCI Cell Manipulation Core Facility

Technical Director, DFCI Immune Effector Cell Therapy Program  ...